Recapping the 2023 RAD and ReV Virtual Conferences

Summit Art Creations/Adobe Stock

Upadacitinib for Vitiligo Improves Patient Health-Related QoL After 24 Weeks

The promising data on upadacitinib was presented at the 2023 Revolutionizing Vitiligo Virtual Conference.

Alan Irvine, MD, DSc: Atopic Dermatitis and the Biological Clock

Alan Irvine, MD, DSc, discusses his Revolutionizing Atopic Dermatitis session and exciting advances in AD.

Study Finds Association Between Vitiligo and Osteoporosis

A poster presented at the 2023 ReV Virtual Conference explored the association between the 2 conditions.

Association Found Between Atopic Dermatitis and Altered Oral Microbiome

A poster from the 2023 Revolutionizing Atopic Dermatitis Conference revealed a link between AD, impaired oral health, and oral dysbiosis.

Patient Perspective: I Am More Than My Atopic Dermatitis

Jennifer Etienne shared her experiences during the shared decision-making patient panel of the 2023 Revolutionizing Atopic Dermatitis Virtual Conference.

5-Year Safety Data Leaves Investigators Optimistic in Upadacitinib for AD Management

Christopher Bunick, MD, PhD, presented the research during a late-breaking research session during the 2023 Revolutionizing Atopic Dermatitis Virtual Conference.

Dupilumab Treatment Improved Epidermal Neuroanatomy in Patients With Atopic Dermatitis

The poster was presented at the 2023 Revolutionizing Atopic Dermatitis (RAD) Virtual Conference.

Raj Chovatiya, MD, PhD: Advancements in Topical Therapies for Atopic Dermatitis

At the 2023 RAD Virtual Conference, Chovatiya presented a session titled, "Living the Cream."